MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by ERLICH, R. H.
Right arrow Articles by CHIGNELL, C. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by ERLICH, R. H.
Right arrow Articles by CHIGNELL, C. F.

Molecular Pharmacology, Vol 9, 61-73, Copyright © 1973 by the American Society for Pharmacology and Experimental Therapeutics

A Spin Label Study of Human Erythrocyte Carbonic Anhydrases B and C

RONALD H. ERLICH 1, DONNAS K. STARKWEATHER 1, and COLIN F. CHIGNELL 1

1 Laboratory of Chemical Pharmacology, National Heart and Lung Institute, National Institutes of Health, Bethesda, Maryland 20014

The topography of the active sites of human erythrocyte carbonic anhydrases (EC 4.2.1.1) B and C has been studied by means of a series of spin-labeled sulfonamide inhibitors. Electron spin resonance measurements indicated that the nitroxide group of 2,2,5,5-tetramethyl-3-[(p-sulfamoylphenyl)carbamoyl]-1-pyrrolidinyloxyl was highly immobilized when this inhibitor bound to the active site of human erythrocyte carbonic anhydrase C. As the chain length between the aromatic and the pyrrolidine rings was increased, the mobility of the nitroxide group of the enzyme-bound inhibitor progressively increased until, with 2,2,5,5-tetramethyl-3-[[[(p-sulfamoylphenyl)carbamoyl]methyl]carbamoyl]-1-pyrrolidinyloxyl, there was only minimal interaction between the free radical and the active site. These results suggest that the active site of human erythrocyte carbonic anhydrase C is a cleft approximately 140 nm deep. Similar experiments indicated that the active site of human erythrocyte carbonic anhydrase B had the same general shape as the C isozyme. Human erythrocyte carbonic anhydrase B, after reaction with a nitroxide analogue of bromacetamide, showed spectral evidence for the presence of fairly mobile and highly immobilized covalently bound spin labels. When spin labeling was carried out in the presence of the inhibitor acetazolamide, the highly immobilized component of the spectrum was abolished, which suggested that it arose from a nitroxide group attached to the active site of the enzyme. When a nitroxide analogue of N-ethylmaleimide reacted with human erythrocyte carbonic anhydrase C, the spin label exhibited a high degree of mobility. Since prior treatment of the enzyme with p-chloromercuribenzoate abolished all labeling by this reagent, it appeared that the spin label had reacted with a sulfhydryl group on the surface of human erythrocyte carbonic anhydrase.

Note:
ACKNOWLEDGMENT One of us (RHE) would like to thank Hoffmann-La Roche, Inc. for a postdoctoral fellowship.

Submitted on July 3, 1972







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1973 by the American Society for Pharmacology and Experimental Therapeutics